Literature DB >> 29631196

Outlooks on Epstein-Barr virus associated gastric cancer.

Madiha Naseem1, Afsaneh Barzi1, Christine Brezden-Masley2, Alberto Puccini1, Martin D Berger1, Ryuma Tokunaga1, Francesca Battaglin3, Shivani Soni1, Michelle McSkane1, Wu Zhang1, Heinz-Josef Lenz4.   

Abstract

Epstein-Barr virus associated gastric cancer (EBVaGC) comprises approximately 10% of gastric carcinomas. Multiple factors contribute to tumorigenesis, including EBV driven hypermethylation of tumor suppressor genes, inflammatory changes in gastric mucosa, host immune evasion by EBV and changes in cell cycle pathways. The unique molecular characteristics of EBVaGC, such as programmed death ligand 1 (PD-L1) overexpression, highlight the potential for using EBV as a biomarker for response to immunotherapy. Few studies have reported benefit from immunotherapy in EBV positive cancers, and clinical trials investigating the impact of checkpoint inhibitors in EBVaGC are currently underway. This review provides the most recent updates on molecular pathophysiology, epidemiology, clinical features and treatment advances pertaining to EBVaGC.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarker; EBV; Gastric cancer; Immunotherapy; PD-L1; Viruses

Mesh：

Year:  2018        PMID： 29631196      PMCID： PMC5964025          DOI： 10.1016/j.ctrv.2018.03.006

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN： 0305-7372            Impact factor:   12.111


  85 in total

1.  Efficacy of PD-1 blockade in tumors with MMR deficiency.

Authors:  Valerie Lee; Dung T Le
Journal:  Immunotherapy       Date:  2015-12-08       Impact factor: 4.196

2.  Downregulation of microRNA-200 in EBV-associated gastric carcinoma.

Authors:  Aya Shinozaki; Takashi Sakatani; Tetsuo Ushiku; Rumi Hino; Maya Isogai; Shunpei Ishikawa; Hiroshi Uozaki; Kenzo Takada; Masashi Fukayama
Journal:  Cancer Res       Date:  2010-05-18       Impact factor: 12.701

3.  Epstein-barr virus detection in tumors of upper gastrointestinal tract. An in situ hybridization study in Pakistan.

Authors:  M Anwar; C Koriyama; I A Naveed; S Hamid; M Ahmad; T Itoh; Y Minakami; Y Eizuru; S Akiba
Journal:  J Exp Clin Cancer Res       Date:  2005-09

4.  Overexpression and gene amplification of PD-L1 in cancer cells and PD-L1+ immune cells in Epstein-Barr virus-associated gastric cancer: the prognostic implications.

Authors:  Ruri Saito; Hiroyuki Abe; Akiko Kunita; Hiroharu Yamashita; Yasuyuki Seto; Masashi Fukayama
Journal:  Mod Pathol       Date:  2016-12-09       Impact factor: 7.842

5.  Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study.

Authors:  Atsushi Ohtsu; Jaffer A Ajani; Yu-Xian Bai; Yung-Jue Bang; Hyun-Cheol Chung; Hong-Ming Pan; Tarek Sahmoud; Lin Shen; Kun-Huei Yeh; Keisho Chin; Kei Muro; Yeul Hong Kim; David Ferry; Niall C Tebbutt; Salah-Eddin Al-Batran; Heind Smith; Chiara Costantini; Syed Rizvi; David Lebwohl; Eric Van Cutsem
Journal:  J Clin Oncol       Date:  2013-09-16       Impact factor: 44.544

6.  Prognostic factors in Epstein-Barr virus-associated stage I-III gastric carcinoma: implications for a unique type of carcinogenesis.

Authors:  Shih-Chiang Huang; Kwai-Fong Ng; Kuang-Hua Chen; Jun-Te Hsu; Keng-Hao Liu; Ta-Sen Yeh; Tse-Ching Chen
Journal:  Oncol Rep       Date:  2014-06-05       Impact factor: 3.906

7.  Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Yoon-Koo Kang; Narikazu Boku; Taroh Satoh; Min-Hee Ryu; Yee Chao; Ken Kato; Hyun Cheol Chung; Jen-Shi Chen; Kei Muro; Won Ki Kang; Kun-Huei Yeh; Takaki Yoshikawa; Sang Cheul Oh; Li-Yuan Bai; Takao Tamura; Keun-Wook Lee; Yasuo Hamamoto; Jong Gwang Kim; Keisho Chin; Do-Youn Oh; Keiko Minashi; Jae Yong Cho; Masahiro Tsuda; Li-Tzong Chen
Journal:  Lancet       Date:  2017-10-06       Impact factor: 79.321

Review 8.  Epigenetic dysregulation in Epstein-Barr virus-associated gastric carcinoma: disease and treatments.

Authors:  Tung On Yau; Ceen-Ming Tang; Jun Yu
Journal:  World J Gastroenterol       Date:  2014-06-07       Impact factor: 5.742

Review 9.  Epstein-Barr Virus and Gastric Cancer Risk: A Meta-analysis With Meta-regression of Case-control Studies.

Authors:  Jong-Myon Bae; Eun Hee Kim
Journal:  J Prev Med Public Health       Date:  2016-03-04

Review 10.  Status of Epstein-Barr Virus Coinfection with Helicobacter pylori in Gastric Cancer.

Authors:  Shyam Singh; Hem Chandra Jha
Journal:  J Oncol       Date:  2017-03-21       Impact factor: 4.375
View more
  46 in total

1.  Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Authors:  Simon Pernot; Magali Terme; Nina Radosevic-Robin; Florence Castan; Cécile Badoual; Elie Marcheteau; Fréderique Penault-Llorca; Olivier Bouche; Jaafar Bennouna; Eric Francois; Francois Ghiringhelli; Christelle De La Fouchardiere; Emmanuelle Samalin; Jean Baptiste Bachet; Christophe Borg; Valérie Boige; Thibault Voron; Trevor Stanbury; Eric Tartour; Sophie Gourgou; David Malka; Julien Taieb
Journal:  Gastric Cancer       Date:  2019-07-02       Impact factor: 7.370

Review 2.  Kinases and therapeutics in pathogen mediated gastric cancer.

Authors:  Charu Sonkar; Nidhi Varshney; Siva Koganti; Hem Chandra Jha
Journal:  Mol Biol Rep       Date:  2022-01-15       Impact factor: 2.316

3.  Prediction and prognostic significance of ALOX12B and PACSIN1 expression in gastric cancer by genome-wide RNA expression and methylation analysis.

Authors:  Zhiping Liu; Lei Li; Xindi Li; Mingtao Hua; Huaqing Sun; Shengui Zhang
Journal:  J Gastrointest Oncol       Date:  2021-10

4.  Transcriptome sequencing of LMP2A-transfected gastric cancer cells identifies potential biomarkers in EBV-associated gastric cancer.

Authors:  Wen Liu; Hua Xiao; Hui Song; Shucai An; Bing Luo
Journal:  Virus Genes       Date:  2022-07-11       Impact factor: 2.198

Review 5.  Signaling pathways and therapeutic interventions in gastric cancer.

Authors:  Zi-Ning Lei; Qiu-Xu Teng; Qin Tian; Wei Chen; Yuhao Xie; Kaiming Wu; Qianlin Zeng; Leli Zeng; Yihang Pan; Zhe-Sheng Chen; Yulong He
Journal:  Signal Transduct Target Ther       Date:  2022-10-08

6.  Clinicopathologic and genomic characteristics of mucinous gastric adenocarcinoma.

Authors:  Jae Eun Lee; Yoon Young Choi; Ji Yeong An; Ki Tae Kim; Su-Jin Shin; Jae-Ho Cheong
Journal:  Gastric Cancer       Date:  2022-05-09       Impact factor: 7.701

7.  Detection and characterization of latency stage of EBV and histopathological analysis of prostatic adenocarcinoma tissues.

Authors:  Khalid Ahmed; Alisalman Sheikh; Saira Fatima; Ghulam Haider; Kulsoom Ghias; Farhat Abbas; Nouman Mughal; Syed Hani Abidi
Journal:  Sci Rep       Date:  2022-06-21       Impact factor: 4.996

Review 8.  Immunosuppressive Tumor Microenvironment and Immunotherapy of Epstein-Barr Virus-Associated Malignancies.

Authors:  Xueyi Zheng; Yuhua Huang; Kai Li; Rongzhen Luo; Muyan Cai; Jingping Yun
Journal:  Viruses       Date:  2022-05-10       Impact factor: 5.818

9.  Single-Cell Sequencing Analysis Based on Public Databases for Constructing a Metastasis-Related Prognostic Model for Gastric Cancer.

Authors:  Rubin Xu; Liang Chen; Wei Wei; Qikai Tang; You Yu; Yiming Hu; Sultan Kadasah; Jiaheng Xie; Hongzhu Yu
Journal:  Appl Bionics Biomech       Date:  2022-04-27       Impact factor: 1.664

10.  Identification of differential proteomics in Epstein-Barr virus-associated gastric cancer and related functional analysis.

Authors:  Zeyang Wang; Zhi Lv; Qian Xu; Liping Sun; Yuan Yuan
Journal:  Cancer Cell Int       Date:  2021-07-12       Impact factor: 5.722
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.